MPN blast phase: Clinical challenge and assessing response

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1496-1497

  Mesa, Ruben A ^a   Tibes, Raoul ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; HISTONE DEACETYLASE INHIBITOR; HYPOMETHYLATING AGENT; JANUS KINASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL; EDITORIAL; GENE; GENE MUTATION; HUMAN; JAK2 GENE; MYELOPROLIFERATIVE NEOPLASM; PATHOGENESIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION;

BLAST CRISIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MUTATION; MYELOABLATIVE AGONISTS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; THROMBOCYTHEMIA, ESSENTIAL; TRANSPLANTATION CONDITIONING;

EID: 84868193773     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.026     Document Type: Editorial

References (10)

1. Mesa R.A., Verstovsek S., Cervantes F., Barosi G., Reilly J.T., Dupriez B., et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007, 31(6):737-740.
2. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13):2895-2901. [Epub 2008/11/08].
3. Mesa R.A., Li C.Y., Ketterling R.P., Schroeder G.S., Knudson R.A., Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105(3):973-977. [Epub 2004/09/25].
4. Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7(9):673-683.
5. Kundranda M.N., Tibes R., Mesa R.A. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?. Curr Hematol Malig Rep 2012, 7(1):78-86. [Epub 2011/12/16].
6. Cherington C., Slack J.L., Leis J., Adams R.H., Reeder C.B., Mikhael J.R., et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012, [Epub 2012/05/15].
7. Thepot S., Itzykson R., Seegers V., Raffoux E., Quesnel B., Chait Y., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010, 116(19):3735-3742.
8. Eghtedar A., Verstovsek S., Estrov Z., Burger J., Cortes J., Bivins C., et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012, 119(20):4614-4618. [Epub 2012/03/17].
9. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108(5):1497-1503. [Epub 2006/05/06].
10. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474. [Epub 2009/11/03].